Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16568 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Mohamad Jamalinia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Aims
Since sex is a significant modifier of cardiovascular disease (CVD) and metabolic dysfunction‐associated steatotic liver disease (MASLD), we performed a meta‐analysis to estimate the sex‐specific risk of fatal and non‐fatal CVD events in adults with MASLD. Materials and Methods We searched four major electronic databases from inception to November 2024 to identify observational cohort studies examining sex‐specific associations between MASLD and the risk of fatal and/or non‐fatal CVD events. The diagnosis of MASLD and its severity were assessed using serum biomarkers/scores, International Classification of Diseases codes, imaging or histology.
Results
Thirty‐six cohort studies with aggregate data on ~18.5 million individuals were included (~25% with MASLD; 48% women; mean age of 50.2 years). During a median follow‐up of 6.9 years (IQR 5.0–12.3), approximately 515 000 fatal and/or non‐fatal CVD events occurred (42% in women). MASLD was associated with a higher risk of fatal or non‐fatal CVD events in women (pooled hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.44–1.75; I 2 = 96.10%) than in men (pooled HR 1.37, 95% CI 1.27–1.48; I 2 = 96.26%) ( p ‐value for sex difference = 0.018). The severity of MASLD (variably assessed) further increased the magnitude of this risk, especially in women (pooled HR 2.40, 95% CI 1.73–3.32; I 2 = 57.29%). Sensitivity analyses did not modify these findings. The funnel plot and Egger's test showed no significant publication bias.
Conclusions
Women with MASLD are at higher risk of incident fatal and non‐fatal CVD events compared with men, especially as the severity of MASLD increases. These findings emphasize the necessity for sex‐specific CVD risk assessment and management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
- Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Verona, Italy.
- Department of Medicine, University of Verona, Verona, Italy.
- Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
ORCID-Profile: Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo
Zitieren
APA
Jamalinia, M., Zare, F., Mantovani, A., Targher, G., & Lonardo, A. (2025). Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16568
Vancouver
Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16568
BibTeX
@article{Jamalinia2025,
author = {Jamalinia, Mohamad and Zare, Fatemeh and Mantovani, Alessandro and Targher, Giovanni and Lonardo, Amedeo},
title = {Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16568}
}
EUVIMED